Chemokine Receptors {#S1}
===================

Chemokine receptors belong to class A 7TM receptors and consist of 350 amino acids on average. Their ligands, the chemokines (8--12 kDa peptides), are divided into two major and two minor groups, depending on the position of two conserved cysteine residues relative to each other. Hence, the two major groups are CCL- (the two cysteines are situated next to each other) and CXCL-chemokines (separated by one amino acid), and the two minor groups are CX~3~CL1 (only one ligand, where there are three amino acids in between the cysteines) and XCLs (two ligands, lacking the first cysteine). The chemokine receptors are grouped according to the ligands they bind, i.e., CCR1-10, CXCR1-6, CX~3~CR1, and XCR1. Presently, there are 18 chemokine receptors and \~40 chemokines acknowledged in the human proteome ([@B1], [@B2]). In addition to these receptors, which all mediate signaling, there are also so-called scavenging receptors, which bind chemokines but have not been shown to mediate intracellular signaling, i.e., ACKR1-4 and CCRL2 (also known as DARC, D6, CXCR7, CCRL1, and CRAM), ([@B2]). These are believed to function as decoy receptors to attenuate the chemokine-induced responses. As the large numbers of receptors and ligands indicate, the chemokine system is highly promiscuous. Thus, several chemokines can bind to the same receptor and vice versa (although some receptor--ligand interactions are highly specific and selective, e.g., CCR9--CCL25 and CXCR6--CXCL16). This promiscuous interaction pattern together with the large number of receptors and ligands enables the chemokine system to propagate a great variety of cell functions. An overview of the human chemokine communication network is given in Figure [1](#F1){ref-type="fig"}.

![**Overview of the promiscuity of the human chemokine system**. Chemokine ligands are listed vertically, while chemokine receptors are listed horizontally. A circle indicates interaction between the receptor and ligand. No receptors are reported for CCL18, CXCL4, and CXCL14. Atypical chemokine receptors are boxed in black on the right. The diagram is constructed based on ([@B144]) and updated to match the database from IUPHAR ([@B2]) and the NCBI gene bank[^1^](#fn1){ref-type="fn"}.](fimmu-05-00277-g001){#F1}

Chemokine receptors are most often Gα~i/o~-coupled; i.e., they inhibit adenylate cyclase and limit the level of intracellular cAMP and activation of PKA. However, other pertussis toxin-sensitive (i.e., Gα~i~-coupled) effects have been shown to occur in response to activation of chemokine receptors, e.g., phosphorylation of ERK1/2 (part of the MAP kinase cascade) ([@B3]--[@B5]) and increase in Ca^2+^ flux, most likely through the Gβγ subunit ([@B6]), which activates PLC-β. Moreover, it has been shown that Gβγ is important for chemokine-induced leukocyte migration ([@B7], [@B8]) possibly through the action of phosphoinositide-3 kinases (PI3K), thereby stimulating the generation of phosphatidylinositol (3--5)-trisphosphate (PIP~3~) ([@B9], [@B10]).

Chemokines are so named because they are chemotactic cytokines, and thus their primary role is to mediate leukocyte chemotaxis. All chemokines, except CXCL16 and CX~3~CL1, which are integral membrane proteins, are soluble proteins. However, to limit their dissemination, chemokines can bind to negatively charged glycosaminoglycans (GAGs), which are attached to proteins on cell surfaces or the extracellular matrix, forming proteoglycan structures. When secreted by, for example, endothelial cells, chemokines tend to remain concentrated and immobilized at tissue sites, and so do not flow freely in the blood. This immobilization of chemokines is vital for the establishment of a chemokine gradient and thus for the recruitment of leukocytes to endothelial cells lining the blood vessels ([@B11], [@B12]). These chemokine gradients can be made up by *homeostatic chemokines*, which are constitutively produced and coordinate general leukocyte circulation important for immune tolerance as well as maintaining the architecture of secondary lymphoid organs, and *inflammatory chemokines*, which only are produced by activated cells and recruit leukocytes to sites of inflammation. However, some chemokines fall into both categories. In addition to cell migration, other biological functions have been ascribed to chemokine receptors, e.g., angiogenic effects ([@B13], [@B14]), cell-adhesion and cell-extravasation ([@B15], [@B16]), as well as anti-apoptotic signaling ([@B17], [@B18]).

Because chemokines and their receptors are highly important in the immune defense, it is not surprising that they have been attributed roles in several autoimmune and inflammatory diseases. In addition, they are implicated in cancer and viral infections, e.g., HIV. As a consequence, chemokine receptors are amenable drug targets. However, at present only clinical trials in inhibition of HIV infection \[the CCR5 antagonist maraviroc ([@B19], [@B20])\] and mobilization of stem cells \[the CXCR4 antagonist plerixafor ([@B21], [@B22])\] have successfully led to marketed drugs. In contrast, the pursuit of chemokine-receptor antagonists as anti-inflammatory compounds has been futile, generally because of lack of efficacy in Phase II clinical trials ([@B23], [@B24]). As the number of successful drug development plans implies, there are great difficulties in targeting chemokine receptors. Because of the promiscuity of the chemokine system it is conceivable, that various chemokines binding to the same receptor, and vice versa, induce different responses ([@B25]). Drug targeting of a single ligand or receptor could therefore be insufficient to obtain the desired response. On the other hand, antagonizing and thus eliminating physiological responses of exclusive chemokine-receptor pairs could have detrimental effects on for example development, as seen in CXCR4^−/−^ neonatal mice ([@B26], [@B27]). In both cases, un-defined targeting of the complete cellular signaling system could be the underlying cause of lack of success. Therefore, *biased ligands* could be a solution. Because these ligands induce or inhibit selective pathways (see below), this form of treatment could potentially eliminate side effects originating from activation of a variety of cellular signaling pathways. In the following, we will discuss signaling bias from a functional and structural point of view.

Biased Signaling in Chemokine Receptors {#S2}
=======================================

*Biased signaling* or *functional selectivity* is a concept, which describes a situation where a 7TM-receptor preferentially activates one of several available cellular signaling pathways. It can be divided into three distinct cases: *ligand bias, receptor bias*, and *tissue* or *cell bias* (Figure [2](#F2){ref-type="fig"}). Biased signaling is regarded as a relatively new concept, even though a review on the serotonergic system was published as early as 1987, speculating on the potential benefits of selective agonists and antagonists possessing specific effects on a particular receptor-linked effector ([@B28]). The concept of biased signaling was introduced by Kenakin in 1995 as "agonist trafficking" ([@B29]). Here, it was proposed that agonists have different affinities toward diverse conformational states of the same receptor, which in turn are coupled to individual effector proteins, inducing various signaling pathways. This hypothesis has lately been backed up by several studies ([@B30]--[@B33]).

![**Overview of different variations of biased signaling**. Biased signaling describes a situation in which a receptor preferentially activates one signaling pathway over another. (Left) Ligand bias is used to differentiate between two ligands acting on the same receptor, where ligand A favorably activates pathway 1, whereas ligand B activates pathway 2. (Center) In receptor bias, the same ligand binds to two different receptors, and activates pathway 1 via receptor A, but pathway 2 through receptor B. (Right) In tissue (or cell) bias, the same ligand: receptor-complex is activated in two different tissues or cell types (or different species), and in tissue A pathway 1 is preferentially activated, whereas pathway 2 is more likely to be activated in tissue B.](fimmu-05-00277-g002){#F2}

Biased signaling can occur both as a result of ligand-induced activation as well as in the absence of a ligand, i.e., via a constitutively active receptor state, as observed for the virus-encoded CXC--chemokine-receptor ECRF3, that signals via Gα~i~ and Gα~q~ in a ligand-dependent manner, but is selective via Gα~i~ when it comes to constitutive activity ([@B34]). Most often, biased signaling is differentiated into G protein-dependent and β-arrestin-dependent signaling.

Ligand biased signaling {#S2-1}
-----------------------

*Ligand bias* describes a situation where different ligands bind the same receptor, but induce diverse responses. One example of ligand bias has been proposed for the two endogenous CCR7 ligands, CCL19 and CCL21, which together are involved in the homing of various T cell subpopulations and antigen-presenting dendritic cells (DCs) to the lymph nodes. Here, the T cells are primed by the DCs to allow their antigen-specific activation ([@B35]). Although CCL19 and CCL21 bind to the same receptor, they are expressed in slightly different tissues (see below). Moreover, they only share 32% amino acid identity, and importantly, CCL21 has a large C-terminal domain of 37 amino acids that are highly positively charged and capable of binding to glycosaminoglycans (GAGs) and thereby immobilizing the chemokine ([@B36], [@B37]). This is in contrast to CCL19, which does not contain this large C-terminal domain. Furthermore, CCL21 was formerly known as 6Ckine, because it has six cysteine residues in contrast to most other chemokines, which only have four. Due to their differential expression pattern and dissimilar structures, it has been speculated that binding of CCL19 and CCL21 to CCR7 induce distinct cellular responses. Indeed, there is general consensus that whereas both ligands are able to activate G protein-signaling, only CCL19 induces internalization of the receptor ([@B5], [@B38], [@B39]). Thus, it has been shown that they have the same efficacy in G protein binding ([@B5]) and Ca^2+^ flux ([@B4]), and also that they show similar efficacy in ERK1/2 phosphorylation ([@B40]) (Steen et al., unpublished work). On the other hand, Ricart and coworkers showed that the quantitative chemotaxis of murine DCs against either CCL19 or CCL21 depended on the relative chemokine concentration ([@B41]). Thus, at a low chemokine concentration gradient (≤20 nM/mm), CCL19 induced migration with a significantly higher chemotactic index (CI) than CCL21. In contrast, at a chemokine concentration gradient of 200 nM/mm, CCL21 induced migration with a higher CI than CCL19 ([@B41]). Furthermore, it has been shown on several occasions that CCL19-mediated β-arrestin recruitment induces receptor internalization whereas CCL21 does not ([@B5], [@B39], [@B40]). Moreover, Zidar et al. found that in spite of no CCL21-induced desensitization, this chemokine was perfectly able to induce β-arrestin-mediated ERK1/2 phosphorylation. They explained this paradox by a marked GPCR kinase (GRK) preference, i.e., GRK3 activity is unique to CCL19, whereas GRK6 is active in an unbiased manner responding to receptor activation by both ligands ([@B40]).

Virus-encoded 7TM receptors often bind a broad spectrum of chemokines, and many cases of ligand bias have been described among these receptors. US28 encoded by human cytomegalovirus binds several human CC-chemokines (CCL1--CCL5), but has particular high affinity for the soluble form of CX~3~CL1 ([@B42]). CCL2--5 act as agonists in some pathways and neutral ligands in others, whereas CX~3~CL1 is a partial inverse agonist in most pathways ([@B43]--[@B49]). Similar phenomena have been observed for the viral CXC-chemokine receptors ECRF3 (from herpesvirus Saimiri) and ORF74 (from human herpesvirus 8) ([@B34], [@B50]--[@B55]).

Recently, an article was published addressing the concept of biased signaling in the chemokine system as a possible means for further fine-tuning of the signaling network ([@B56]). The authors tested whether different ligands targeting the same receptor displayed bias between G protein-signaling, β-arrestin recruitment, and internalization. They found that at CCR10, CCL28 acted as a G protein-biased agonist, while the other endogenous ligand, CCL27 signaled through both G protein and β-arrestin. Furthermore, from a qualitative bias plot they calculated that at CXCR3, CXCL9 appears to be relatively β-arrestin-biased, while CXCL11 is biased toward internalization. That CXCL11 is the strongest and physiologically most relevant inducer of internalization was already suggested in 2001 ([@B57]). A similar phenomenon was described for CXCR2, as CXCL8 was reported to be much more efficient in receptor internalization compared to CXCL7 ([@B58]) despite having equally high CXCR2 affinities ([@B59]). Later, structural data revealed that the three CXCR3 ligands mediate internalization through different receptor regions. In particular, it was shown that CXCL9- and CXCL10-induced internalization requires serine/threonine residues (putative phosphorylation sites) on the receptor C terminus, whereas CXCL11-induced internalization depends on the third intracellular receptor loop ([@B60]). The actual binding sites and overall receptor motifs involved in the binding of the CXCR3 chemokines also vary, as CXCL10 is much more dependent on residues located in the transmembrane helices, i.e., in the deeper receptor regions. Thus, in a study probing the molecular intra-helical requirements for receptor activation in CXCR3 by creating an artificial small molecule binding-site, CXCL11 was "resistant" to most mutants in the helices, whereas CXCL10 binding was severely impaired ([@B61]). A similar picture was obtained when the AMD3100 binding-site was successfully transferred from CXCR4 to CXCR3 ([@B62]). Finally, a recent study showed that CXCL10 and CXCL11 activate distinct downstream signaling mediators, and lead to a clearly divergent CD4^+^ T cell polarization. Importantly, this bias was demonstrated to be of profound importance for the treatment of experimental autoimmune encephalomyelitis (EAE) in mice, as CXCL11 alone was able to suppress perivascular lesions arising as a result of EAE ([@B63]).

The literature also describes incidents of ligand bias in posttranslationally modified chemokines. An example of this is observed for CCL14 and different truncated isoforms binding to the atypical (or scavenging) chemokine-receptor ACKR2. The inactive full-length isoform CCL14 (1--74) binds to ACKR2 but is not internalized and degraded, and does not induce up-regulation of the receptor to the cell surface. This is in stark contrast to the active truncated version CCL14 (9--74), which promotes up-regulation of ACKR2 surface expression and is subsequently degraded, presumably through a G protein-independent, β-arrestin-dependent Rac1--PAK1--LIMK1--cofilin signaling cascade ([@B64], [@B65]). The authors conclude that a proline in position 2 of CCL14 (9--74) is critical for CCL14 degradation and receptor trafficking. In general, chemokine binding to their cognate receptors is postulated to follow a two-step mechanism ([@B66]--[@B68]). The primary interaction, which provides high-affinity binding to the receptor, is mediated via the chemokine core-domain including the N-loop that follows the conserved cysteine-motif. The second step is an interaction of the ligand N terminus, preceding the first cysteine, with various receptor domains and this is essential for the subsequent receptor activation. In the case of CCL14, the authors propose that a similar interaction occurs between CCL14 and ACKR2. Here, the second step is characterized by the interaction of the second proline of CCL14 (9--74) with the transmembrane bundle of ACKR2, which leads to β-arrestin recruitment and CCL14 degradation. Thus, in the absence of this step, as is the case for the inactive CCL14 (1--74), where the proline is not readily accessible, receptor trafficking is not affected ([@B64]). Hence, truncated CCL14 is a ligand biased toward a β-arrestin-dependent activation of the Rac1--PAK1--LIMK1--cofilin signaling pathway. Chemokines undergo other posttranslational modifications, e.g., glycosylation, sulfation, and citrullination \[reviewed in Ref. ([@B69])\]. It is highly likely that these modifications also can induce biased signaling, enabling different versions of the same chemokine to signal through alternative pathways.

An additional posttranslational event is chemokine dimerization -- a phenomenon that also influences chemokine-receptor signaling. For example, at CXCR4 there are distinct signaling patterns associated with monomeric or dimeric CXCL12 that can either promote or inhibit chemotaxis, respectively ([@B70]). While monomeric and dimeric CXCL12 activated G protein-dependent signaling (i.e., Ca^2+^ flux and inhibition of forskolin-induced cAMP production) with similar efficacy, the preferential monomeric form of CXCL12 induced a greater response in β-arrestin recruitment and chemotaxis. Moreover, whereas activation of CXCR4 by monomeric CXCL12 resulted in a slower increase in ERK1/2 phosphorylation, dimeric CXCL12 induced a rapid and transient phosphorylation ([@B70]).

As CXCR4 is one of the primary coreceptors for HIV infection, many compounds targeting this receptor have been synthesized. One example is the class of pepducin molecules, which are lipid-modified peptides derived from the amino acid sequences of one of the three intracellular loops of a target 7TM receptor ([@B71]). One of these pepducins, ATI-2341, has been shown to act as a biased agonist on CXCR4, being able to induce β-arrestin coupling but not Gα~i~ signaling in contrast to CXCL12 ([@B72]). Thus, also synthesized compounds can exhibit biased properties.

Receptor biased signaling {#S2-2}
-------------------------

*Receptor bias* refers to the case where the same ligand induces different responses on different receptors. For example, the chemokine CXCL12 has been shown to bind to both CXCR4 and ACKR3. CXCR4 was originally thought to be the sole receptor for CXCL12 in the otherwise promiscuous chemokine system. As mentioned above, CXCL12 induces activation of both Gα~i~ ([@B73]) and β-arrestin via CXCR4 ([@B74], [@B75]). In 2005, it was discovered that CXCL12 also bind to ACKR3 ([@B76]), but this chemokine receptor was thought to act as a scavenger, sequestering CXCL12 inside the cell, as no immediate G protein-signaling was observed for this ligand:receptor interaction ([@B77], [@B78]). However, it was soon discovered that CXCL12 is able to activate β-arrestin-mediated *signaling* in ACKR3 ([@B79]), and this distinguishable activation on ACKR3 with respect to CXCR4 makes it the first case of endogenous receptor biased signaling.

Along those lines, atypical chemokine receptors have been described as being able to bind a variety of chemokines but without eliciting Gα~i~ signaling. They were originally thought to regulate the amount of free chemokine available to bind to chemokine receptors (i.e., "scavenge") and thus dampen an immune response. However, incidents have since been described -- as for ACKR2 -- where they might be able to induce G protein-independent intracellular signaling. ACKR2 binds most inflammatory CC-chemokine agonists of CCR1--5 ([@B80]) and no G protein-signaling has been recorded upon binding of any of them. Although β-arrestin-dependent signaling has not been described for all the chemokine ligands, it is conceivable that this form of biased signaling occurs in other incidents than the described ACKR2--CCL14 interaction (see above).

A different side to chemokine-receptor bias is the discovery that several chemokines, which have been dubbed natural *agonists* for some chemokine receptors, act as natural *antagonists* for other chemokine receptors. One example is the chemokines targeting CXCR3, i.e., CXCL9, -10, and -11, which originally were shown to be selective agonists for this receptor. However, it has been shown that the three ligands are able to displace the binding of CCL11 on CCR3-expressing cells ([@B81]). Moreover, they are all able to inhibit CCL11-induced CCR3^+^-cell migration and (cytoplasmic) \[Ca^2+^*~i~*\] changes with no intrinsic activity, and in addition, neither of the CXCR3 agonists induces CCR3 internalization, and thus lack agonistic effects but act as full antagonists ([@B81]). In another setting, it has been shown that CXCL11 also acts as a CCR5 antagonist that inhibits the binding of CCL3 to CCR5-transfected cells and reduces cell migration in response to CCL5 and CCL4, the latter being a selective agonist for CCR5. In addition to the abovementioned examples, a range of other chemokines have been described as natural antagonists, e.g., CCL26 on CCR1 and -5 ([@B82]), CCL18 on CCR3 ([@B83]), CCL7 on CCR5 ([@B84]), CCL4 on CCR1 ([@B85]), and CCL11 and CCL26 on CCR2 ([@B86], [@B87]). For CCL11, the action is even more complex, as it also activates certain pathways in CCR2 ([@B88]). It remains to be determined if these antagonistic (and complex agonistic) properties can be explained by the lack of (or altered) secondary step(s) in the two-step activation mechanism for chemokine receptors.

Viral chemokine receptors display biased signaling relative to their human counterparts responding to the same ligand. For example, CX~3~CL1 is an inverse agonist at US28 via Gα~q~, although it is a full agonist for the endogenous receptor CX~3~CR1 via Gα~i~ ([@B46], [@B89]). Likewise, CXCL6, -10, and -12 are inverse agonists for ORF74--HHV8 via Gα~q~ ([@B52]--[@B54]) but full agonists on their cognate human receptors via Gα~i~ ([@B73], [@B90]--[@B92]). Finally, receptor bias also occurs between viral receptors as observed for ORF74--HHV8 and ECRF3--HVS, where various CXCLs bind with different efficacies and initiate different pathways in these two receptors ([@B34], [@B50], [@B54], [@B55], [@B93], [@B94]).

Tissue bias {#S2-3}
-----------

*Tissue bias* (also referred to as *system or cell bias*) covers the phenomenon in which a ligand for a given receptor activates different pathways in a tissue/cell-specific manner -- or in a species-specific manner. The phenomenon has been described in non-chemokine class A 7TM receptors, e.g., in the β-adrenergic receptors, where Kenakin and coworkers observed a system bias ([@B95], [@B96]). Although there has not been much focus on tissue bias *in vivo*, it is very likely that efficiency of coupling to various cellular pathways is tailored to the needs of the cell. For example, the two endogenous ligands for CCR7, CCL21, and CCL19, show variation in their expression pattern (described above); i.e., CCL19 is expressed by mature DCs, whereas CCL21 is expressed in afferent lymphatic vessels, and they are both present in the lumen of high endothelial venules (HEVs) and on stromal cells of the lymph nodes ([@B97]--[@B99]). Their differential expression pattern and very diverse structures indicate individual roles for the two chemokines. Indeed, different articles disclosing the role of CCL19 in chemotaxis show that the efficacy is cell-type-dependent; CCL19 is able to induce chemotaxis of DCs ([@B41]), whereas CCR7 expressing T lymphocytes are unable to migrate to secondary lymphoid tissue in response to this chemokine ([@B100]). Thus, CCL19 has a differing role in inducing chemotaxis depending on cell type, and these results might be extrapolated to other chemokines.

Another example of tissue bias is seen for the CXCR4-specific small molecule ligand AMD3100 that was originally designed as an antagonist hindering the ability of HIV to interact with CXCR4 and thus infect the cell. The binding mode of AMD3100 in CXCR4 has been thoroughly characterized; it not only inhibits the binding of HIV, but also that of the CXCR4-specific antibody 12G5 and CXCL12, and thereby also inhibits the CXCL12-induced Gα~i~ activation and intracellular Ca^2+^ release ([@B62], [@B101]--[@B105]). These results were achieved by using SUP-T1 cells or COS-7 cells. On the other hand, AMD3100 has been reported to act as a *partial* agonist on WT CXCR4 in a Ca^2+^ release assay, and with even higher efficacy on a constitutively active CXCR4 mutant in THP-1 cells ([@B106]). Thus, as well as being a biologically integrated beneficial phenomenon for tissues *in vivo* (like CCR7 and CCL19/CCL21), tissue bias can be an obstacle when trying to determine the efficacy of a ligand/receptor *in vitro* or *ex vivo*. Hence, to be fully able to determine the biased nature of a ligand or a receptor, comparison between the ligand/receptor-complex in the same tissue or cell type is vital; lessons that are important in particular for drug discovery within 7TM receptors (see below).

Structural Basis for Biased Signaling in Chemokine Receptors, and in Class A 7TM Receptors in General {#S3}
=====================================================================================================

As other membrane proteins, 7TM receptors are highly dynamic and exist in several functionally distinct conformations ([@B107]). Yet, it is generally acknowledged that the activation of all class A 7TM-receptor subclasses involves the same overall helical movements ([@B108]--[@B110]) and that specific domains, so-called micro-switches, regulate these movements ([@B111], [@B112]). In order to develop drugs targeting a limited number of the signaling pathways of a given receptor (biased drugs), it is vital to understand, which residues are important for ligand binding and subsequent receptor interaction with different intracellular effector molecules. Hence, much attention has been focused on disclosing the conformations of 7TM receptors interacting with either the G proteins or β-arrestins, both by developing "static" pictures of active and inactive receptor conformations by X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, but also in obtaining a more dynamic view of the activation process by employing structure--function studies. The only chemokine-receptor structures that have been published are of CXCR4 ([@B113]), CCR5 ([@B114]), and CXCR1 ([@B115]) and none of them have been in complex with an effector molecule. Hence, these structures do not describe, which receptor conformations are able to bind to either G protein or β-arrestin. However, the chemokine-receptor structures share an overall three-dimensional shape with other class A 7TM receptors and therefore, it is conceivable that results from these structures can be transferred to the chemokine receptors.

Interactions with G protein {#S3-4}
---------------------------

The recently published crystal structure of the β~2~-adrenergic receptor in complex with agonist and G protein was the first truly active G protein-coupled 7TM receptor to be disclosed ([@B116]). As suggested by Rasmussen et al., engagement of the G protein by the receptor leads to dramatic changes in the Gα subunit, which in turn forces displacement and stabilizes the β~2~-adrenergic helices TM-5 and -6, curving TM-6 extensively outward (Figure [3](#F3){ref-type="fig"}) ([@B116], [@B117]). The β~2~-adrenergic receptor/agonist/G protein complex also reveals that the interface between the G protein and the receptor involves ICL-2 in addition to TM-5 and -6. Importantly, the structure shows that there is no interaction between the receptor and the Gβγ subunit and furthermore, that there is no interaction between the G protein and TM-7 and helix-8 of the receptor.

![**Activation of a 7TM receptor**. The active β~2~-adrenergic receptor with TM-5 and -6 or -7 highlighted in blue according to their importance for receptor interaction with G protein or β-arrestin, respectively. The structures are visualized with Molsoft Browser Pro©.](fimmu-05-00277-g003){#F3}

Receptors in complex with ligands activating β-arrestin {#S3-5}
-------------------------------------------------------

Most of the 7TM-receptor crystal structures published so far have focused on G protein activation, as the ligands employed have been known as G protein agonists. Furthermore, most crystals have been obtained with truncated and/or otherwise modified receptors. Although β-arrestin has been crystallized in complex with the phosphorylated C-terminal tail of vasopressin ([@B118]), no structure of β-arrestin (or the protein kinase A or C, PKA or PKC, or the G protein-coupled receptor kinases, GRKs, responsible for C-terminal receptor phosphorylation) in complex with an entire 7TM-receptor has yet been crystallized. As such, the required ligand-induced receptor conformation priming β-arrestin is difficult to delineate. However, recently published structures of the β~1~-adrenergic receptor ([@B119]) and the serotonin 5-HT~2B~ receptor ([@B120]) have been in complex with agonists, which preferentially initiate β-arrestin-signaling. The structure of ergotamine (ERG) in complex with either 5-HT~2B~ or 5-HT~1B~ was compared, and ERG acts as a β-arrestin-biased agonist on 5-HT~2B~ but *unbiased agonist* (equal potency and efficacy in G protein- and β-arrestin-signaling) on 5-HT~1B~. This enabled the authors to pinpoint molecular characteristics in the β-arrestin-favorable receptor conformation. By comparing the two structures with the β~2~-adrenergic receptor/agonist/G protein structure, they were able to deduce, which domains of the two serotonin receptors adopted an active-like conformation. They discovered large changes both in overall helical rearrangements as well as in micro-switches \[amino acid sequence motifs that are highly conserved in the class A 7TM-receptor family, i.e., PIF (Pro--Ile--Phe) in TM-3, -5, and -6, D/ERY (Asp/Glu--Arg--Tyr) in TM-3, and NPxxY (Asn--Pro--x--x--Tyr) in TM-7\]. For example, in the β~2~-adrenergic receptor:agonist:G protein complex, the PIF motif was seen to significantly change conformation from the inactive structure and while all these changes also occurred in 5-HT~1B~, only the active-like conformation of ProV:16/5.50[^2^](#fn2){ref-type="fn"} and IleIII:16/3.40, but not PheVI:09/6.44, was observed in 5-HT~2B~. In addition, the ionic lock formed by the D/ERY motif in inactive 5-HT receptor structures was broken in 5-HT~1B~ but not in 5-HT~2B~. In contrast, both serotonin receptors (5-HT~1B~ and 5-HT~2B~) displayed active-state conformations of the conserved NPxxY motif in TM-7, but with more pronounced activation features in the 5-HT~2B~ receptor. Importantly, overall helical changes indicated that whereas the 5-HT~2B~/ERG structure showed less pronounced active-like changes in TM-6, TM-7 appears to be in a more active conformation than in the 5-HT~1B~/ERG structure. Accordingly, the authors deduced that while TM-6 is extremely important for G protein binding \[in agreement with the active structures of the β~2~-adrenergic receptor ([@B116], [@B121])\], TM-7 is highly involved in β-arrestin coupling (Figure [3](#F3){ref-type="fig"}). Along those lines, it was observed that the β-arrestin-biased β~1~-adrenergic receptor agonists, carvedilol and bucindolol compared to unbiased β~1~-adrenergic agonists such as isoprenaline, interacted with additional residues in TM-7 and ECL-2 ([@B119], [@B122]).

The molecular mechanisms that occur in G protein and/or beta-arrestin recruitment are further substantiated in a recent publication concerning the delta-opioid receptor ([@B123]). Here the authors addressed the role of a transmembrane asparagine residue (N131 in position III:11/3.35). When substituting this with alanine (N131A), the receptor lost the ability to signal through Gα~i~, but constitutively ([@B124], [@B125]) recruited β-arrestin. Thus, this mutation generated a receptor with biased signaling as compared to WT delta-opioid receptor; a phenomenon that at the molecular level was coupled to loss of the sodium ion coordination in the mutated receptor.

In addition to the published structures, dynamic studies, such as structure--function studies or spin labeling, have indicated, which receptor domains are involved in G protein and β-arrestin binding. For example, a study employing site-specific ^19^F-NMR labels in the β~2~-adrenergic receptor showed that the cytoplasmic ends of TM-6 and TM-7 adopt two conformational states depending on whether the receptor is in complex with β-arrestin-biased ligands or non-biased ligands. Hence, unbiased agonists primarily induce shifts toward the active state of TM-6, while β-arrestin-biased agonists predominately impact the conformational states of TM-7 ([@B31]). In the chemokine world, mutational studies have primarily been used to gain knowledge about domains relevant for activation. A mutagenesis study in CCR5 showed that mutation of R126 in the DRY motif (in the bottom of TM-3) to a neutral amino acid abolished CCR5-mediated G protein activation, but induced a higher level of receptor phosphorylation and β-arrestin coupling, thus producing a β-arrestin-biased receptor ([@B126]). Lack of G protein activation, while retaining β-arrestin coupling, resembles the signaling pattern of the atypical chemokine receptor as discussed above. Interestingly, these receptors often differ from conventional chemokine receptors in the highly conserved DRYLAIV motif. However, it has been shown on several occasions that "correction" of the variations in the DRYLAIV motif in the atypical chemokine receptors does not induce G protein-signaling through these receptors. For example, replacing the ACKR3 ICL-2 with that of CXCR4 -- and thus exchanging DRYLSIT with DRYLAIV -- did not enable ACKR3 to activate the G protein-dependent signaling pathways ([@B127]). Moreover, modifications of the DRYLAIV motif are also seen in the chemokine receptors XCR1 and CXCR6, which have been shown to signal through pertussis toxin-sensitive Gα~i~ protein ([@B128], [@B129]). Thus, lack of or a mutated DRYLAIV motif does not represent a reliable indicator for the lack of G protein coupling, and indeed, the chemokine receptors that lack the conserved arginine in the DRY motif \[like the CXCL receptor encoded by equine herpesvirus 2 (ORF74-EHV2)\] also signal through G proteins ([@B130], [@B131]). Similarly, a recent study showed that this conserved arginine indeed is dispensable for G protein-signaling in the β~2~-adrenergic receptor ([@B132]).

Helical Movements and Micro-Switches Involved in CCR5 Activation of Different Signaling Pathways {#S4}
================================================================================================

We have recently described transmembrane residues of importance for G protein-signaling and β-arrestin binding in CCR5 ([@B133], [@B134]). In brief, insertion of a steric hindrance mutation in either the center of TM-5 (L203F, in position V:13/5.47) or in TM-7 (G286F, in position VII:09/7.42) resulted in constitutive Gα~i~ activity and increased the affinities of endogenous chemokines. A computational model of \[G286F\]-CCR5 revealed that the conserved tryptophan in TM-6 (W248 in CCR5, part of the CWxP-motif) changed orientation away from TM-7 compared to WT. The essential role of W248 in CCR5 activation was supported by complete inactivity of \[W248A\]-CCR5. Thus, the altered positioning of W248 -- induced by G286F -- led to a constraint of a more agonist-prone nature. On the other hand, a conformational change of a conserved hydrophobic residue in position III:16/3.40 in TM-3 (I116 in CCR5) was observed in an *in silico* model of \[L203F\]-CCR5. Furthermore, a sliding movement of Y244 in TM-6 (position VI:09/6.44) toward TM-5 was observed. *In vitro*, \[I116A\]-CCR5 displayed the same level of constitutive activity as \[L203F\]-CCR5, whereas \[Y244A\]-CCR5 could not be activated. This could indicate that I116 serves a gating function for Y244 movement toward L203, which is important for G protein-signaling. A similar role of these two residues was previously described for other class A 7TM receptors \[i.e., the ghrelin receptor, GPR119, NK-1, and the β~2~-adrenergic receptor ([@B135])\]. Both ligand-dependent and -independent β-arrestin recruitment was eliminated in \[G286F\]- and \[W248A\]-CCR5, indicating biased signaling. In contrast, \[I116A\]- and \[L203F\]-CCR5 were able to recruit β-arrestin both in the presence and absence of agonist. Thus, tampering with the interplay between TM-3 and -5 increases the level of both Gα~i~ signaling and β-arrestin recruitment, while manipulation of the interface between TM-6 and -7 increases G protein-signaling, reduces β-arrestin recruitment and hence, induces biased signaling (Figure [4](#F4){ref-type="fig"}).

![**Biased activity in CCR5**. **(A,B)** Dose--response curves showing the aplaviroc-mediated activation and inhibition of CCR5 WT (purple), \[L203F\]-CCR5 (dark blue), and \[G286F\]-CCR5 (light blue) in G protein and β-arrestin-signaling. Aplaviroc was tested with (full lines) or without (dotted lines) the endogenous ligand CCL3. **(C,D)** Computational models of the WT and mutant receptors depicting the difference in side chain conformations of important amino acids. **(E,F)** Helical wheel diagrams showing the positions of relevant amino acids.](fimmu-05-00277-g004){#F4}

In the abovementioned CCR5-studies, characterization of constitutive activity and activation in response to small molecule ligands on signaling revealed that the CCR5 antagonist aplaviroc underwent an *efficacy switch*, i.e., from being antagonist in G protein-signaling on WT to an agonist on \[L203F\]- and \[G286F\]-CCR5. However, as this switch was not observed in β-arrestin recruitment aplaviroc acted as a biased agonist on these mutants (Figure [4](#F4){ref-type="fig"}), indicating that receptor domains can regulate coupling to different pathways independently as also observed in the delta-opioid receptor. Using compounds like aplaviroc for structure--function experiments provides valuable tools to gain knowledge of the specific receptor domains and ligand structures that induce biased signaling.

Conclusion {#S5}
==========

The experimental results discussed in this review illustrate that biased signaling is a complex phenomenon and that it exists to a large degree in the chemokine system. Biased signaling can occur in different forms; signaling can vary (1) with the ligand, (2) with the receptor, and (3) with the tissue or cell type (or species). All three factors should be taken into consideration when designing, developing, and testing new compounds targeting a component in the chemokine system as well as in the overall 7TM-receptor family. For example, when testing a potential pharmaceutical product *in vitro*, it is not enough to assess its properties against only one endogenous agonist, nor is it sufficient to measure the activity through one signaling pathway. Furthermore, if the target of interest is expressed in diverse tissues it is necessary to ensure that the observed response is identical in other tissues or cell types. In many cases bias is not absolute, i.e., full activation of one pathway and no activation of another. Often, there is activation in all pathways tested and varying efficacies and/or potencies can be defined as a bias. This variation can of course be caused by a natural preference, but it can also be due to cell type (if the different outputs are measured in different cell types) or sensitivity of the assay type. Therefore, it is important to compare efficacies and/or potencies within the assay and cellular systems and thus obtain a bias output that is relative.

The chemokine system is an obvious target for biased ligands due to the high degree of redundancy where multiple ligands bind to the same receptor and therefore potentially elicit an array of intracellular signaling patterns. Thus, designing a selective compound for one signaling pathway would in theory lower the side effects that would arise when inhibiting/activating all signaling pathways. The redundancy of the chemokine system is however impedimental when designing chemokine-targeting drugs, as (1) other ligand--receptor combinations can have a compensating function, and (2) as drugs may be selective for one, but not all chemokines for a given receptor \[e.g., in CCR1, where small molecule ligands acted as positive allosteric modulators with respect to CCL3, but at the same time competed against CCL5 ([@B136])\]. Furthermore, small drug-like substances may act differently on homologous chemokine receptors, as observed in CCR1 and CCR5, where a chloro-terpyridine-based compound acted as agonist with no allosteric properties on CCR1, but with the opposite phenotype on CCR5 ([@B137]). This compound was developed from the bipyridine and phenanthroline-based non-selective CCR1, -5, and -8 ago-allosteric compounds ([@B137], [@B138]).

Chemokines mainly interact with extracellular receptor regions ([@B68]), and therefore the two conformationally constraining disulfide bridges have a major impact on chemokine binding ([@B113], [@B115], [@B139]). Yet, the roles of these bridges vary -- even between homologous chemokine receptors like CCR1 and CCR5 ([@B139]) and thereby contribute to the explanation for why small drug-like substances act differently on (1) different chemokines for the same receptor ([@B136]) or (2) different chemokine receptors ([@B137], [@B138]). These pharmacodynamic challenges combined with the redundancy of the chemokine system may be central for the lack of success when it comes to the development of anti-inflammatory compounds targeting chemokine receptors. *Biased ligands* could be a solution with a directed action on a specific chemokine-receptor domain, and thereby preferential targeting of a single intracellular pathway. This more focused action could potentially eliminate lack of drug efficiency caused by redundancy and chemokine cross-talk, and also eliminate side effects stemming from unspecific activation of a variety of cellular signaling pathways.

Interestingly, biased ligands have been developed in other receptor systems, especially in the cardiovascular system. For example, carvedilol is an unspecific β-blocker with especially good clinical efficacy. It has been shown to be an inverse agonist in Gα~s~-signaling while it stimulates phosphorylation of the C-terminal tail and concomitant β-arrestin recruitment and internalization as well as ERK1/2 activation in HEK-293 cells ([@B140]). Furthermore, carvedilol has been shown to transactivate epidermal growth factor receptor (EGFR, a receptor tyrosine kinase) and mediate ERK1/2 activation in a G protein-independent fashion ([@B141]). The transactivation of EGFR has been shown to be cardioprotective ([@B142]), whereas chronic β-adrenergic receptor coupling to Gα~s~ is thought to be cardiotoxic ([@B143]) and this might explain the unique clinical profile of carvedilol.

In conclusion, deciphering the mechanisms behind biased signaling, including which receptor domains and ligand compositions are responsible for activation of one effector molecule over another is crucial when designing and developing potent and specific 7TM-receptor pharmacotherapeutics. In the chemokine system, signaling bias is abundant in all three forms: ligand, receptor, and tissue (cell/species) bias. With this continuous uncovering of signaling bias in the chemokine system, it becomes clear that the apparent redundancy, which seems inevitably coupled with this system, may be a superficial phenomenon. Instead, the concept of promiscuity may be more correct, and it would be prudent to consider that promiscuous chemokines and their receptors likely have context-defined and separate roles, including the possibility for different functional outcomes of seemingly redundant interactions.
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